Insider Selling: Moderna, Inc. (NASDAQ:MRNA) CEO Sells 9,000 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) CEO Stephane Bancel sold 9,000 shares of the stock in a transaction that occurred on Wednesday, January 12th. The stock was sold at an average price of $220.01, for a total value of $1,980,090.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Stephane Bancel also recently made the following trade(s):

  • On Wednesday, December 29th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $240.00, for a total value of $2,160,000.00.
  • On Wednesday, December 22nd, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $264.26, for a total value of $2,378,340.00.
  • On Wednesday, December 15th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $272.11, for a total value of $2,448,990.00.
  • On Wednesday, December 8th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $282.35, for a total value of $2,541,150.00.
  • On Wednesday, December 1st, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $329.91, for a total value of $2,969,190.00.
  • On Friday, November 26th, Stephane Bancel sold 10,000 shares of Moderna stock. The stock was sold at an average price of $319.62, for a total value of $3,196,200.00.
  • On Wednesday, November 24th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $273.01, for a total value of $2,457,090.00.
  • On Wednesday, November 17th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $234.57, for a total value of $2,111,130.00.
  • On Wednesday, November 3rd, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $350.00, for a total value of $3,150,000.00.
  • On Wednesday, October 27th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $344.25, for a total value of $3,098,250.00.

MRNA opened at $204.73 on Friday. The stock has a fifty day moving average of $259.66 and a 200-day moving average of $320.60. The firm has a market capitalization of $83.01 billion, a P/E ratio of 12.55, a PEG ratio of 0.28 and a beta of 1.22. Moderna, Inc. has a 12-month low of $117.34 and a 12-month high of $497.49. The company has a quick ratio of 1.25, a current ratio of 1.35 and a debt-to-equity ratio of 0.02.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 4th. The company reported $7.70 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $9.49 by ($1.79). Moderna had a net margin of 59.69% and a return on equity of 121.61%. The business had revenue of $4.97 billion during the quarter, compared to analysts’ expectations of $6.29 billion. During the same quarter in the previous year, the company earned ($0.59) EPS. Moderna’s revenue for the quarter was up 3065.0% on a year-over-year basis. On average, analysts expect that Moderna, Inc. will post 26.32 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the stock. Beaumont Asset Management L.L.C. raised its holdings in shares of Moderna by 1.1% during the third quarter. Beaumont Asset Management L.L.C. now owns 2,813 shares of the company’s stock worth $1,082,000 after acquiring an additional 31 shares in the last quarter. Coastal Investment Advisors Inc. raised its holdings in shares of Moderna by 4.7% during the third quarter. Coastal Investment Advisors Inc. now owns 895 shares of the company’s stock worth $344,000 after acquiring an additional 40 shares in the last quarter. Asset Dedication LLC raised its holdings in shares of Moderna by 5.8% during the third quarter. Asset Dedication LLC now owns 760 shares of the company’s stock worth $292,000 after acquiring an additional 42 shares in the last quarter. Glassman Wealth Services raised its holdings in shares of Moderna by 13.6% during the third quarter. Glassman Wealth Services now owns 360 shares of the company’s stock worth $139,000 after acquiring an additional 43 shares in the last quarter. Finally, Fulton Breakefield Broenniman LLC raised its holdings in shares of Moderna by 2.4% during the third quarter. Fulton Breakefield Broenniman LLC now owns 1,955 shares of the company’s stock worth $752,000 after acquiring an additional 45 shares in the last quarter. Institutional investors and hedge funds own 59.11% of the company’s stock.

A number of brokerages recently issued reports on MRNA. SVB Leerink reissued a “sell” rating on shares of Moderna in a report on Thursday, December 23rd. Cowen initiated coverage on Moderna in a research note on Monday, December 6th. They set a “market perform” rating and a $250.00 price target for the company. Argus decreased their price target on Moderna from $420.00 to $350.00 in a research note on Thursday, January 6th. Morgan Stanley decreased their price target on Moderna from $337.00 to $313.00 and set an “equal weight” rating for the company in a research note on Friday, November 5th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $395.00 price target on shares of Moderna in a research note on Friday, November 5th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and an average price target of $251.81.

Moderna Company Profile

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Recommended Story: What are the advantages to having securities held in street name?

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.